REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $80K invested in REGENERX BIOPHARMACEUTICALS in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
82% more capital invested
Capital invested by funds: $44K → $80K (+$36K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WJA
Williams Jones & Associates
New York
|
+$51K |
Top Sellers
RGN Hedge Fund Activity: Q2 2016 in Review
2 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q2 2016, worth a combined $80K — up 82% from $44K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Williams Jones & Associates, opening a new position worth an estimated $51K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q2 2016, up from 1 in Q1 2016.
- Funds reported $80K of REGENERX BIOPHARMACEUTICALS stock for Q2 2016, up 82% quarter-over-quarter.
- 1 fund opened new REGENERX BIOPHARMACEUTICALS positions in Q2 2016 and 0 closed out, a net change of +1 holder.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q2 2016 was Williams Jones & Associates, an estimated $51K added.
Based on aggregated 13F filings for Q2 2016.